PUK16 COST-UTILITY ANALYSIS OF MIRABEGRON VERSUS ANTIMUSCARINIC THERAPY IN THE TREATMENT OF OVERACTIVE BLADDER
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.2700
https://www.valueinhealthjournal.com/article/S1098-3015(19)35078-8/fulltext
Section Title :
Section Order :
12373
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)35078-8&doi=10.1016/j.jval.2019.09.2700